MOSCOW (Sputnik) – The Russian Health Ministry has authorized phase 1 and 2 clinical trials of EpiVacCorona-N, one more coronavirus vaccine developed by the Vector research center, according to the ministry’s register.
“An open study of the safety, tolerability, reactogenicity and immunising power of the EpiVacCorona-N peptide antigen-based vaccine for preventing COVID, involving volunteers aged 18-60 (phase 1-2),” the register read.
The trials started on April 8 and are set to end on September 30.
The EpiVacCorona vaccine, developed by the Vector State Research Centre of Virology and Biotechnology, is a peptide-based drug that relies on a promising synthetic platform. It consists of artificially synthesised short fragments of viral proteins – peptides, through which the immune system learns how to recognise and then neutralise the virus.